Stephanie Moore

Stephanie Moore has a diverse and extensive work experience in the field of medical writing and regulatory operations. Stephanie is currently working at AN2 Therapeutics as the Executive Director of Medical Writing and Regulatory Operations since February 2023, after serving as the Senior Director in the same department from November 2021 to February 2023. Prior to AN2 Therapeutics, Stephanie was the Senior Director of Medical Writing at Taysha Gene Therapies from July 2021 to November 2021, and at Astellas Gene Therapies from August 2019 to June 2021. Stephanie also held the position of Director of Medical Writing at CytomX Therapeutics from January 2019 to August 2019. From May 2015 to January 2019, Stephanie was the Head of Medical Writing at Prothena Biosciences. Stephanie gained significant experience and expertise in medical writing at various levels of management during their time at Cerexa from January 2011 to December 2014 and at Elan Pharmaceuticals from March 2008 to January 2011. Stephanie started their career at Eli Lilly in March 2001 as a Senior Scientific Communications Associate and later served as a Team Leader in Clinical Operations from May 2007 to February 2008. Stephanie's early work experience includes their role as a Cancer Control Manager at Marion County Health Department from 1999 to 2002. Through their extensive career, Stephanie has demonstrated their skills and expertise in medical writing and regulatory operations, contributing to the success of various organizations in the biotech and pharmaceutical industries.

Stephanie Moore pursued their education at Indiana Wesleyan University from 1992 to 1996, where they obtained a Bachelor's degree in Biology. Subsequently, between 1997 and 1998, they attended Ball State University to earn a Master's degree in Health Science with a specialization in Community Health Education.